In the Phase III DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) and Perjeta (pertuzumab) significantly improved ...

The trial aims to assess the safety and efficacy of Enhertu, either as a single agent or with pertuzumab, against the THP.

IQVIA also found there were 50 other mechanisms of action being evaluated in the clinic, with 43% being oral therapies, 55% parenteral therapies, and 2% administered in another way. 3 Big news is ...

Enhertu (fam-trastuzumab deruxtecan-nxki) is currently indicated as a second-line therapy for HER2-positive metastatic breast cancer.

The PFS benefit with T-DXd was observed across all prespecified patient subgroups. Overall survival (OS) data were not mature ...

Circle Pharma to Present Late-Breaking Data at AACR 2025 Demonstrating Mechanism of Action for Novel Cyclin A/B RxL Inhibitors Circle Pharma, a clinical-stage biopharmaceutical company focused on ...

Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive ...

Circle Pharma, a clinical-stage biopharmaceutical company focused on developing cell-permeable macrocycle therapeutics, today announced a late-breaking poster presentation at the American ...

Huo Xue Tong Luo Capsule (HXTL) has been clinically used to treat osteonecrosis of the femoral head, osteoporosis, and other bone and joint diseases with promising effects.